Microbial pattern and antimicrobial resistance, a surgeon's perspective: Retrospective study in surgical wards and seven intensive-care units in two university hospitals in Cairo, Egypt

Dermatology

Volumn 212, Issue SUPPL. 1, 2006, Pages 8-14

  Saied, Gamal Moustafa ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Antibiotics; Antimicrobial resistance; Bacterial susceptibility; Egypt

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CROSS INFECTION; EGYPT; ESCHERICHIA COLI; FEMALE; HOSPITAL SUBDIVISIONS AND COMPONENTS; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; PSEUDOMONAS; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STATISTICS; SURGERY;

BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EGYPT; ESCHERICHIA COLI; FEMALE; HOSPITAL UNITS; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS; SURGERY;

EID: 33745279457     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000089193     Document Type: Conference Paper

References (33)

1. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Echman MR, Farrer WE, Greene WH, Lorian V, Levy S, Mc-Gowan JE Jr, Paul SM, Fred JR, Tenover C, Watanakunakorn C: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clin Infect Dis 1997; 25: 584-599.
2. Priest P, Yudkin P, McNulty C, Mant D: Antibacterial prescribing and antibacterial resistance in English general practice: cross sectional study. BMJ 2001; 323: 1037-1041.
3. Eggimann P, Pittet D: Infection control in the ICU. Chest 2001; 120: 2059-2093.
4. El Kholy A, Baseem H, Hall GS, Procop GW, Longworth DL: Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. J Antimicrob Chemother 2003; 51: 625-630.
5. Brooke T: Antimicrobial resistance - A public health threat accounting 2005. http://home.rochester.rr.com/tebrooke/Pageeight.html.
6. World Health Organization: Report on Infectious Diseases. Removing obstacles to healthy development. 1999 Infectious Disease Report. Geneva, WHO, 1999.
7. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y: Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101: 2916.
8. Maki DG, Stolz SM, Wheeler S, Mermel LA: Infection prevention of central venous catheter-related bloodstream infection. A randomized controlled trial. Ann Intern Med 1997; 127: 257-266.
9. Pfaller MA: Epidemiology of candidiasis. J Hosp Infect 1995; 30(suppl):329-338.
10. Micek ST, Lloyd AE, Ritchie DJ, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-1311.
11. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH: A nationwide multicenter case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000; 36: 145-158.
12. Conterno LO, Wey SB, Castelo A: Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998; 19: 32-37.
13. Pezzlo M: Aerobic bacteriology; in Isenberg HD (ed): Clinical Microbiology Procedures Handbook. Washington, American Society for Microbiology, 1992, pp 1191-2047.
14. Reisner SB, Woods GL, Thomson RP Jr, Larone DH, Garcia LS, Shimuzu RY: Specimen collection; in Baron EJ, et al (eds): Manual of Clinical Microbiology, ed 7. Washington, American Society for Microbiology, 1999, pp 64-76.
15. Shannon KP, French GL: Increasing resistance to antimicrobial agents of gram-negative organisms isolated at a London teaching hospital, 1995-2000. J Antimicrob Chemother 2004; 53: 818-825.
16. Nation2006;212(suppl 1):l Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. Wayne, NCCLS, 1997.
17. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard M2-A6. Wayne, NCCLS, 1997.
18. Pfaller MA, Jones RN, Doern GV, Kugler K, and the Sentry Participant Group: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada) 1997. Antimicrob Agents Chemother 1998; 42: 1762-1770.
19. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, et al: The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998; 42: 489-495.
20. Reimer K, Wichelhaus TA, Schäfe V, Rudolph P, Kramer A, Wutzler P, Ganzer D, Fleischer W: Antimicrobial effectiveness of povidoneiodine and consequences for new application areas. Dermatology 2002; 204: 114-120.
21. Harbarth S, Ferrière K, Hugonnet S, Ricou B, Suter P, Pittet D: Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002; 137: 1353-1359.
22. Hemsell DL, Johnson ER, Bawdon RE, et al: Ceftriaxone and cefazolin prophylaxis for hysterectomy. Surg Gynecol Obstet 1985; 161: 197-203.
23. Flamm RK, Weaver MK, Thornsberry C, Jones ME, Karlowsky JA, Sahm DA: Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004; 48: 2431-2436.
24. Carmeli Y, Troillet N, Karchmer A, Samore M: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-1132.
25. Harris A, Torres-Viera C, Venkataraman L, De Girolami P, Samore M, Carmeli Y: Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-1133.
26. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681-1688.
27. Chen DK, McGeer A, de Azavedo JC, Low DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
28. Lee BL, Kimbrough RC, Jones SR, Chaisson RE, Mills J: Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 520-521.
29. Gruneberg RN, Felmingham D: Results of the Alexander project: a continuing multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-181.
30. Simor AE, Louie M, Low DE: Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae: Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 1996; 40: 2190-2193.
31. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L: High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40: 2760-2764.
32. Oliphant CM, Green GM: Quinolones: a comprehensive review. Am Fam Physician 2002; 65: 455-464.
33. el-Teheawy MM, el-Bokl MA, Abd el-Fattah SA, Sabbour MS: The pattern of antimicrobial use in general hospitals in Egypt. Chemioterapia 1998; 7: 387-392.